Aerie Pharmaceuticals Logo

News Releases

Date Title View
Toggle Summary Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan   and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million , up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2022-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
Webinar to be held Friday, September 23, 2022   @   10 a.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced
View HTML
Toggle Summary Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1 Adds Rocklatan ® and Rhopressa ® , and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770
View HTML
Toggle Summary Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 15, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million , up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022   Aerie Expects to be Cash Flow Break Even During 2024 DURHAM, N.C.DURHAM ,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2022-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 28, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after
View HTML
Toggle Summary Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--May 25, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan , Chief Executive Officer, along with Peter Lang ,
View HTML
TOP